Companies › Immatics Biotechnologies
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMA401 TCER® (T cell engineered receptor) targeting MAGE-A4 and/or MAGE-A8 | MAGE-A4, MAGE-A8 | Phase 1 | Refractory Cancer | Sep 2027 |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) | – | Phase 1 | Refractory Cancer | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05958121 | IMA402 | Phase 1 | Refractory Cancer | Oncology | Sep 2027 |
| NCT05958121 | IMA401 | Phase 1 | Refractory Cancer | Oncology | Sep 2027 |
| NCT05359445 | IMA401 | Phase 1 | Refractory Cancer | Oncology | Dec 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.